Ipsen 

Ipsen S.A. is a global biopharmaceutical enterprise specializing in the development and commercialization of therapeutic solutions. The company's focus areas include cancer treatment (oncology), neurological conditions, digestive health (gastroenterology), cognitive impairments, and various rare disorders. Its specialized pharmaceutical portfolio encompasses treatments for oncology and rare disorders, featuring Somatuline (for neuroendocrine tumors and acromegaly), Decapeptyl (for advanced prostate cancer), Cabometyx (for renal cell carcinoma and certain hepatocellular carcinomas), Onivyde (for metastatic pancreatic cancer), Xermelo (for carcinoid syndrome), and Cometriq (for medullary thyroid cancer). In neurological care, Dysport addresses motor muscular disorders and finds application in medical aesthetics. For growth hormone deficiencies, Ipsen offers NutropinAq, indicated for growth failure in children (including those with GH deficiency, Turner syndrome, or chronic renal failure) and adult GH deficiency, alongside Increlex for growth failure in children and adolescents. The company's diverse gastrointestinal and consumer health segment includes Smecta (for chronic/acute diarrhea and functional bowel pain), Forlax (for constipation), and Fortrans/Eziclen (for bowel preparation prior to medical examinations or surgery). Other products in this area are SmectaGas (for symptomatic relief of gas-related GI issues), Etiasa (for inflammatory bowel diseases), and the Smebiocta/SmectaFlora Protect food supplement. Furthermore, Tanakan is offered for cognitive disorders in adults, vertigo, and tinnitus. Ipsen's broader consumer healthcare range for digestive health features products such as Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. To further its research and commercial reach, Ipsen S.A. maintains strategic collaborations and alliances with numerous partners, including Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Established in 1929, the company's corporate headquarters are situated in Boulogne-Billancourt, France.